Corbus Pharmaceuticals

Update in progress

CRBP (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company developing therapies for cancer and obesity. Its pipeline includes CRB-701, an antibody-drug conjugate that targets Nectin-4 on tumor cells to deliver the cytotoxic payload monomethyl auristatin E, and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity. Founded in 2009, it is based in Norwood, Massachusetts.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive